De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

StageZero Life Sciences Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

James Howard-Tripp

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.2yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	16.4yrs

Recente managementupdates

Recent updates

Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% Higher

Jan 25

CEO

James Howard-Tripp

8.2yrs

Tenure

US$270,000

Compensatie

Mr. James R. Howard-Tripp has been the Executive Chairman of StageZero Life Sciences Ltd. (formerly known as GeneNews Limited) (also known as ChondroGene Ltd.) since July 12, 2013 and has been its Chief Ex...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Howard-Tripp	Executive Chairman & CEO	22.8yrs	US$270.00k	0.19% $ 9.3k
Rory Riggs	Independent Director	24.8yrs	US$40.00k	10.15% $ 501.6k
Garth A. MacRae	Independent Director	24.4yrs	US$40.00k	0.12% $ 5.9k
Lawrence Cohen	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	geen gegevens	geen gegevens
David Sidransky	Member of Colorectal Cancer Clinical Advisory Board	no data	geen gegevens	geen gegevens
Khursheed Jeejeebhoy	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	geen gegevens	geen gegevens
Harry Glorikian	Independent Director	16.4yrs	US$40.00k	0.087% $ 4.3k
Richard Wender	Member of Colorectal Cancer Clinical Advisory Board	no data	geen gegevens	geen gegevens
Bernard Levin	Chairman of Colorectal Cancer Clinical Advisory Board	17.3yrs	geen gegevens	geen gegevens
David Lieberman	Member of Colorectal Cancer Clinical Advisory Board	no data	geen gegevens	geen gegevens
Barry Stein	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	geen gegevens	geen gegevens
Jeffrey Baker	Member of Colorectal Cancer Clinical Advisory Board	15.9yrs	geen gegevens	geen gegevens

16.4yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SZLS zijn ervaren en ervaren (gemiddelde ambtstermijn van 16.4 jaar).

StageZero Life Sciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Stagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COO

Insufficient new directors

StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022

StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021

Recent updates

Insufficient new directors

StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)

StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer Offerings

New major risk - Share price stability

Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer Offerings

Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)

StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023

Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)

Insufficient new directors

StageZero Life Sciences Ltd. to Report Q3, 2022 Results on Nov 15, 2022

StageZero Life Sciences Ltd. announced that it has received CAD 0.177 million in funding

Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021)

StageZero Life Sciences Ltd. to Report Q2, 2022 Results on Aug 16, 2022

Stagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COO

First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021)

StageZero Life Sciences Ltd. to Report Q1, 2022 Results on May 17, 2022

Insufficient new directors

StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020)

StageZero Life Sciences Ltd. Launches AVRT Program for Patients Living in the United Kingdom

StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022

StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022

StageZero Life Sciences Ltd. announced that it has received CAD 1.87 million in funding

StageZero Life Sciences Ltd. announced that it expects to receive CAD 1.87 million in funding

StageZero Life Sciences Ltd. announced that it has received CAD 4.200001 million in funding

StageZero Life Sciences Ltd. announced that it expects to receive CAD 4.200001 million in funding

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020)

StageZero Life Sciences Ltd. (TSX:SZLS) completed the acquisition of All Assets of Health Clinics Limited and Health Clinics USA Corp.

Interim Chief Financial Officer Carl Solomon has left the company

Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020)

Stagezero Life Sciences Offers Drive-Up, COVID-19 PCR Travel Testing with Results Reported the Same Day

First quarter 2021 earnings released

Full year 2020 earnings released

StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021

New 90-day high: CA$1.45

Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% Higher

New 90-day high: CA$0.92

New 90-day low: CA$0.63

StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 10.000068 million.

StageZero Life Sciences Ltd. to Report Q3, 2020 Results on Nov 18, 2020

StageZero Life Sciences Ltd. to Provide Rapid Testing Services for Travelers from U.S. and Canada

StageZero Life Sciences Ltd. Launches Saliva PCR Testing for the Detection of the SARS-COV-2 Virus

New 90-day high: CA$0.87

First half earnings released

StageZero Life Sciences Ltd. to Report Q2, 2020 Results on Aug 14, 2020

StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 4.632327 million.

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd